Using Satralizumab to treat complications from brain aneurysms.
Satralizumab as a Treatment for Aneurysmal Subarachnoid Hemorrhage (the STASH Trial)
This study is looking at how well the drug Satralizumab can help people recover after a brain aneurysm by reducing complications like vasospasm, and it’s designed for patients who have had this type of hemorrhage.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-10952347 on NIH RePORTER |
What this research studies
This research investigates the use of Satralizumab, a drug that modulates the inflammatory response, to treat patients who have experienced an aneurysmal subarachnoid hemorrhage. The study aims to reduce vasospasm, a condition that can lead to severe complications after a brain aneurysm rupture. By assessing various biomarkers, behavioral outcomes, and imaging data, the research seeks to understand the drug's effectiveness in improving patient recovery and reducing long-term damage. This trial represents a significant step in translating laboratory findings into clinical practice.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have recently experienced an aneurysmal subarachnoid hemorrhage and are at risk for vasospasm.
Not a fit: Patients who have not experienced an aneurysmal subarachnoid hemorrhage or those with other unrelated neurological conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly improves recovery and reduces complications for patients who suffer from aneurysmal subarachnoid hemorrhage.
How similar studies have performed: Previous research has shown promising results in modulating inflammatory responses in similar conditions, indicating potential for success in this novel approach.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Hoh, Brian Lim — University of Florida
- Study coordinator: Hoh, Brian Lim
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.